Home
Archives
Vol. 2022 No. 1-2 (2022)

/

/

/

Research articles

Evaluating the frequency of types of myasthenia gravis, age, gender and treatment based on the type of antibody effective in myasthenia gravis of heart failure patients

Keivan Basiri
Isfahan Neuroscience Research Center, Alzahra Research Institute, Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran.

Behnaz Ansari
Neuroscience Research Centre, Neurology Department, Isfahan University of Medical Sciences, Isfahan, Iran.

Koorosh Parchami
Isfahan University of Medical Sciences, School of Medicine, Isfahan, Iran (M.D)

Anahita mobin
Isfahan University of Medical Sciences, Department of Cardiology, Isfahan, Iran.

Mohammad Ghoreishi
Isfahan University of Medical Sciences, Department of Cardiology, Isfahan, Iran.

https://doi.org/10.21558/gcsp.2022.11
Abstract

Introduction: Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction caused by the production of antibodies against muscle specific kinase enzyme (MuSK), or acetylcholine receptor (AChR). These antibodies are the reason for weakness, easy fatigability and atrophy of the muscles. MG is a common disease that understanding of the antibodies, their clinical manifestations and their outcomes to be very important.

Methods: Patients visiting the outpatient for clinic for myasthenia gravis followup were enrolled in this study after signing a consent form. Demographic characteristic and their medical history was accessed and extracted. Patients who had undergone thymectomy. We are reporting the pathologic results of the said thymectomy surgeries. Information regarding the treatments of the patients were also accessed from their files and then analyzed.

Results: We found the most common antibody to be acetylcholine receptor anti-AChR, followed by anti-MuSK and seronegative patients in the following ranks. we found that autoantibodies found in the patient blood is independent of age and gender, and they are not correlated with MG type. The type of treatment used was also independent of the antibodies found in the patient. only rituximab was more likely to be prescribed in seropositive patients.

Discussion: Anti MuSK is less frequent, with more severe symptoms and generalized weakness while the results were not significant. We found Anti-MuSK MG and Anti-AChR, to be similar in treatment, clinical and thymectomy patients in the groups were similar and no difference was seen.

PDF
Published
2022-12-15

Section
License

This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

Vol. 2022 No. 1-2 (2022)
Open Journal Systems
Information
For Readers
For Authors
For Librarians

​​​DOI:

Issue
Research articles